PRISM MEDICO AND PHARMACY LTD. is a Finance company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY19 |
|---|---|
| Revenue | 54 |
| EBITDA (ex other income) | 0 |
| margin % | 0.2 |
| Owners' profit | 0 |
| EPS, as reported (₹) | 0.07 |
| ROE % · ROCE % | 0.3 · 0.1 |
| Debt / equity (x) | 0.18 |
| Cash from operations | — |
| Capex | — |
| ₹ crore | Q1 FY19 | Q2 FY19 | Q3 FY19 | Q4 FY19 | Q1 FY20 | Q2 FY20 | Q3 FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | 6 | 15 | 17 | 17 | 9 | 7 | 10 |
| Profit before tax | 0 | 0 | 0 | (1) | 0 | 0 | (0) |
| Net profit | 0 | 0 | 0 | (1) | 0 | 0 | (0) |
| EPS (₹) | 0.53 | 0.46 | 0.24 | (1.07) | 0.21 | 0.15 | (0.07) |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| BAJAJ FINANCE LIMITED | 6,43,552 | 31.7 | 5.50 | 11.6 | 16.5 | — | 25.2 | 70.7 |
| SHRIRAM FINANCE LIMITED | 2,42,019 | 18.1 | 3.67 | 6.7 | 15.2 | — | 22.5 | 74.7 |
| CHOLAMANDALAM IN & FIN CO | 1,57,446 | 27.2 | 5.17 | 6.9 | 17.2 | — | 26.5 | 71.2 |
| TATA CAPITAL LIMITED | 1,54,110 | 28.2 | 3.27 | 6.5 | 10.4 | — | — | 75.8 |
| MUTHOOT FINANCE LIMITED | 1,12,094 | 9.9 | 2.82 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 26 Aug 2026 · AGM notice: Rs 23 cr from capex shifted to related-party investment | results | medium | — | — |
| 24 Aug 2026 · Book Closure for 24th AGM from Sep 13 to Sep 19, 2026 | board shareholder meetings | low | — | — |
| 24 Aug 2026 · Book closure for 24th AGM from Sep 13 to Sep 19, 2026 | corporate actions | low | — | — |
| 24 Aug 2026 · Annual Report FY26 with variation of preferential issue and related party investment | results | high | — | — |
| 24 Aug 2026 · FY26 Annual Report and AGM Notice with subsidiary acquisition proposal | compliance | medium | — | — |
| 24 Aug 2026 · 24th AGM notice on Sept 19, 2026; key item: Rs 23 cr reallocation to related party IWPL | board shareholder meetings | low | — | — |
| 24 Aug 2026 · Board approves FY26 Director's Report, 24th AGM on Sept 19, preferential issue variation | board shareholder meetings | low | — | — |
| 19 Aug 2026 · Board Meeting on Aug 24, 2026 for Annual Results and AGM Items | board shareholder meetings | low | — | — |
| 12 Aug 2026 · Board approves Q1 FY27 results, net loss at Rs 5.83 lakh | board shareholder meetings | medium | — | — |
| 5 Aug 2026 · Board meeting on 12 Aug 2026 to consider Q1 FY27 results | results | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 3.9 |
| 26.7 |
| — |
| 22.0 |
| 84.0 |
| SBI CARDS & PAY SER LTD | 62,349 | 27.4 | 3.96 | — | 13.8 | — | — | 33.1 |
| HDB FINANCIAL SERVICES L | 55,706 | 20.2 | 2.70 | — | 12.3 | — | — | 58.0 |
| SUNDARAM FINANCE LTD | 52,217 | 23.3 | 3.51 | 6.7 | 13.8 | — | — | 78.4 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 3.1 | 1.1 | 196 of 245 | 20% |
| ROCE | 1.2 | 2.1 | 40 of 63 | 37% |
| ROE | 1.2 | 3.0 | 171 of 266 | 36% |
| Debt / Equity | 0.0 | 0.0 | 5 of 266 | 11% |
| EBITDA margin | 0.3 | 48.6 | 191 of 249 | 23% |
| Revenue growth | (43.0) | 12.6 | 188 of 231 | 19% |
| Profit growth | (130.2) | 7.8 | 199 of 251 | 21% |
| Market cap | 40 | 37 | 127 of 260 | 51% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
